Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.

Poullenot F, Ollivier J, Rivière P, Sauvaget L, Berroneau A, Djabarouti S, Xuereb F, Zerbib F, Breilh D, Laharie D.

Dig Liver Dis. 2019 Dec 21. pii: S1590-8658(19)30927-2. doi: 10.1016/j.dld.2019.11.018. [Epub ahead of print]

PMID:
31874834
2.

Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?

Ollivier J, Carrié C, d'Houdain N, Djabarouti S, Petit L, Xuereb F, Legeron R, Biais M, Breilh D.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02134-18. doi: 10.1128/AAC.02134-18. Print 2019 Mar.

3.

A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two internal standard calibration approaches.

Legeron R, Xuereb F, Chaignepain S, Gadeau AP, Claverol S, Dupuy JW, Djabarouti S, Couffinhal T, Schmitter JM, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec 1;1070:43-53. doi: 10.1016/j.jchromb.2017.10.042. Epub 2017 Oct 23.

PMID:
29111437
4.

Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases.

Streicher C, Djabarouti S, Xuereb F, Lazaro E, Legeron R, Bouchet S, Greib C, Breilh D, Pellegrin JL, Viallard JF.

Br J Clin Pharmacol. 2014 Dec;78(6):1419-25. doi: 10.1111/bcp.12462.

5.

Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage.

Legeron R, Xuereb F, Djabarouti S, Saux MC, Breilh D.

Am J Health Syst Pharm. 2013 Dec 1;70(23):2137-42. doi: 10.2146/ajhp120372.

PMID:
24249764
6.

Lower 12-hour trough concentrations of mycophenolic acid in patients with active systemic vasculitides taking mycophenolate mofetil.

Djabarouti S, Lazaro E, Breilh D, Pellegrin JL, Viallard JF.

J Rheumatol. 2012 Nov;39(11):2222-3. doi: 10.3899/jrheum.120606. No abstract available.

PMID:
23118295
7.

Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, Saux MC, Allaouchiche B.

J Antimicrob Chemother. 2012 May;67(5):1207-10. doi: 10.1093/jac/dks022. Epub 2012 Feb 20.

PMID:
22351682
8.

A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.

Mosnier-Thoumas S, Djabarouti S, Xuereb F, Lazaro E, Pellegrin JL, Saux MC, Breilh D.

J Pharm Pharmacol. 2011 Dec;63(12):1559-65. doi: 10.1111/j.2042-7158.2011.01368.x.

PMID:
22060286
9.

Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.

Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF.

Arthritis Res Ther. 2010;12(6):R217. doi: 10.1186/ar3202. Epub 2010 Dec 22. Erratum in: Arthritis Res Ther. 2011;13(2):401.

10.

Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.

Expert Opin Pharmacother. 2010 Apr;11(5):689-99. doi: 10.1517/14656561003592144.

PMID:
20210680
11.

Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.

Breilh D, Djabarouti S, Trimoulet P, Le Bail B, Dupon M, Ragnaud JM, Fleury H, Saux MC, Thiébaut R, Chêne G, Neau D.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):428-30. doi: 10.1097/QAI.0b013e3181b62858. No abstract available.

PMID:
19858925
12.

Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C.

Breilh D, Foucher J, Castéra L, Trimoulet P, Djabarouti S, Merrouche W, Couzigou P, Saux MC, de Lédinghen V.

Aliment Pharmacol Ther. 2009 Sep 1;30(5):487-94. doi: 10.1111/j.1365-2036.2009.04065.x. Epub 2009 Jun 11.

13.

Diffusion of ertapenem into bone and synovial tissues.

Boselli E, Breilh D, Djabarouti S, Bel JC, Saux MC, Allaouchiche B.

J Antimicrob Chemother. 2007 Oct;60(4):893-6. Epub 2007 Aug 17.

PMID:
17704514
14.

Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients.

Boselli E, Breilh D, Djabarouti S, Guillaume C, Rimmelé T, Gordien JB, Xuereb F, Saux MC, Allaouchiche B.

Intensive Care Med. 2007 Sep;33(9):1519-23. Epub 2007 May 25.

PMID:
17530217
15.

Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).

Djabarouti S, Breilh D, Pellegrin I, Lavit M, Camou F, Caubet O, Fleury H, Saux MC, Pellegrin JL.

J Antimicrob Chemother. 2006 Nov;58(5):1090-3. Epub 2006 Aug 18.

PMID:
16921181
16.

Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B.

Crit Care Med. 2005 Jul;33(7):1529-33.

PMID:
16003058
17.

Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.

Boselli E, Breilh D, Rimmelé T, Djabarouti S, Saux MC, Chassard D, Allaouchiche B.

Crit Care Med. 2005 Jan;33(1):104-9.

PMID:
15644655
18.

Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.

Rouzes A, Berthoin K, Xuereb F, Djabarouti S, Pellegrin I, Pellegrin JL, Coupet AC, Augagneur S, Budzinski H, Saux MC, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):209-16.

PMID:
15556535
19.

Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method.

Toutain J, Boselli E, Djabarouti S, Allaouchiche B, Xuereb F, Bernadou JM, Ba B, Saux MC, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):145-50.

PMID:
15556527
20.

Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.

Breilh D, Jougon J, Djabarouti S, Gordien JB, Xuereb F, Velly JF, Arvis P, Landreau V, Saux MC.

J Chemother. 2003 Dec;15(6):558-62.

PMID:
14998080
21.

Diffusion of levofloxacin into bone and synovial tissues.

Rimmelé T, Boselli E, Breilh D, Djabarouti S, Bel JC, Guyot R, Saux MC, Allaouchiche B.

J Antimicrob Chemother. 2004 Mar;53(3):533-5. Epub 2004 Feb 12.

PMID:
14963066
22.

Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method.

Djabarouti S, Boselli E, Allaouchiche B, Ba B, Nguyen AT, Gordien JB, Bernadou JM, Saux MC, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):165-72.

PMID:
14659449

Supplemental Content

Loading ...
Support Center